Surgery plays an important role in the treatment of anterior mediastinum disease. The major surgical approaches include: cervical approach, mid-sternal approach, cervical combined mid-sternal approach and video-assisted thoracoscopic approach. The cervical approach is rarely adopted because of its restricted visual field. The cervical combined mid-sternal approach have a broader field of vision, given this advantage, the surgeon can remove the thymus and its surrounding fat tissue more thoroughly. But the trauma of this approach is much larger, and the postoperative complication is also a serious problem. The video-assisted thoracoscope is often adopted by left or right approach, this minimally invasive procedure can not remove anterior mediastinum fat thoroughly. In clinical practice, the investigators designed a new method named "3-Hole" subxiphoid approach. This study is designed to compare the safety and validity between this new method and others.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
240
"3-Hole" subxiphorid and subcostal approach anterior mediastinum tumor resection
Trans sternal approach anterior mediastinum tumor resection
Video-assisted thoracoscope anterior mediastinum tumor resection
Tangdu hospital
Xi'an, Shaanxi, China
RECRUITINGAmount of bleeding
Measured by the difference between the wet weight and dry weight of surgical gauze
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
Rate of conversions to thoracotomy
Only in "3-Hole" subxiphorid group and VATS group
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
Duration of operation
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
Mortality rate
Death caused by operation or complications
Time frame: up to 10 years
Overall survival
From randomization to any cause of death
Time frame: up to 10 years
Quality of life
Measured by EORTC QLQ-C30 (version 3) scale
Time frame: up to 10 years after operation
Number of Participants with Adverse Events
Time frame: up to 8weekss afte operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.